StockGlow

Iovance Biotherapeutics, Inc. (2LB.F)

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

3.93-0.01%Healthcare
Compare 2LB.F with
StockGlow Score
87
Bullish
BearishBullish
1 year ago+81.0%

The outlook

Iovance Biotherapeutics, Inc. currently reads as bullish based on above its 50- & 200-day averages, 74% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.

What’s behind the score

Price trendAbove its 50- & 200-day averages
52-week range74% of the way from its 52-week low to high
Market cap
$1.75B
52-wk high
4.74
52-wk low
1.57
50-day avg
3.72
200-day avg
2.84
Trailing P/E
—

Similar stocks

2L9.FVisionWave Holdings, Inc.$1.63-4.13%0JDK.LIovance Biotherapeutics, Inc.$4.32-9.62%26CA.FImmunityBio, Inc.$6.59+2.81%38I.FIntellia Therapeutics, Inc.$9.30+1.53%UP0.FUltragenyx Pharmaceutical Inc.$22.52+4.89%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy